Twice-Yearly Injectable for HIV Prevention Approved in US The US FDA has approved Gilead Sciences’ lenacapavir, a twice-yearly injectable for HIV prevention. This significant milestone offers new hope for ending the HIV epidemic, with plans for a global rollout, including in low-income nations. **Focus Keywords:** HIV prevention, lenacapavir, Yeztugo, PrEP, Gilead Sciences, FDA approval, global…